Held
OSCR · Oscar Health, Inc.
Last analysed ·
Against its published line
Nothing is through its line on this close.
How to read this
The red mark is the published kill line — the price that would prove the pick wrong. The dot is where the name closed on 10 September 2026; a dot LEFT of the mark has closed through its line.
Distance is drawn on a square-root scale, so close calls get the room. Past 8% a row stops competing and reads well clear, with a hollow dot to say the figure is off the drawn scale. Rows run tightest first.
Current thesis
Oscar Health's next valuation leg needs quantified 2027 growth at its September 16, 2026 Investor Day. Confirmation requires that disclosure and a subsequent weekly close above $32.76 before a weekly close below $29.83; absence of the specified growth framework also ends the case.
Kill line
A weekly close below $29.83 breaks the post-August 6 earnings structure. Separately, September 16, 2026 passing without either a quantified 2027 membership range or a quantified 2027 premium framework ends the information-catalyst thesis.
Pick status
Open commitment catalyst in 5dscored if the kill line above fires How this is scored →Latest analysis and events for OSCR —
As of 10 September 2026, the latest FrontierPicks analysis for Oscar Health, Inc. (OSCR): Oscar Health's next valuation leg needs quantified 2027 growth at its September 16, 2026 Investor Day. Confirmation requires that disclosure and a subsequent weekly close above $32.76 before a weekly close below $29.83; absence of the specified growth framework also ends the case.
Kill line: A weekly close below $29.83 breaks the post-August 6 earnings structure. Separately, September 16, 2026 passing without either a quantified 2027 membership range or a quantified 2027 premium framework ends the information-catalyst thesis.
Next dated event on file: — catalyst in 5d.
Current Thesis
Oscar Health's next valuation leg depends on quantified 2027 growth at its September 16, 2026 Investor Day, followed by a weekly close above $32.76 before a weekly close below $29.83 invalidates the case. This is an inference about an information catalyst: the company's July 28 announcement promises long-term financial targets but does not specifically promise a 2027 membership range or premium framework. Company announcement.
The September 9, 2026 adjusted daily close of $31.76 is back below the $32.76 August high identified in the preceding published assessment. That reverses the September 8 daily advance above the threshold; the required post-event weekly confirmation remains unresolved. These are observations from the dated adjusted price series, not evidence that the earnings improvement has reversed.
The narrative is maturing — the August 6 earnings improvement is now being tested against the September 16 growth-framework disclosure. This classification is an inference from the disclosure sequence, not a measured claim about fund flows.
Bullish and bearish views on Oscar Health, Inc.
The model's bull view on Oscar Health, Inc. (OSCR), in brief: Operating earnings establish the recovery. The bear view: Reserve revisions complicate recurring profitability. Both cases follow in full.
Bull Case
- Operating earnings establish the recovery. Oscar's August 6, 2026 release reported second-quarter operating earnings of $388.6 million, versus an operating loss of $230.5 million in the second quarter of 2025. Earnings release.
- The annual outlook also improved. On August 6, 2026, management raised full-year operating-earnings guidance to $500–700 million and lowered medical loss ratio guidance to 81.5–82.5%. The medical loss ratio measures medical expenses relative to net premiums before ceded quota-share reinsurance. These are management forecasts, not completed annual results. Earnings release.
Bear Case
- Reserve revisions complicate recurring profitability. The August 6, 2026 release attributed part of the second-quarter medical loss ratio improvement to $164 million of favorable revisions to prior-period claims reserves. The quarter therefore does not establish recurring underwriting performance on its own. Earnings release.
- Required growth details remain unpromised. The July 28, 2026 announcement names long-term financial targets without specifying the disclosures required by this thesis. September 16 passing without either a quantified 2027 membership range or a quantified 2027 premium framework would invalidate the information-catalyst case. Company announcement.
Setup & Price Structure
The September 9, 2026 adjusted series records a $31.76 daily close, 3.8% below its $33.01 52-week high, alongside a three-month price increase of 14.0%. The close is below the existing $32.76 confirmation threshold and above the $29.83 weekly-close invalidation boundary retained from the September 9 published research. Proximity to the high alone does not establish a sustained breakout.
Retail breakout commentary appeared on September 9, 2026 in both r/trading212 and r/Wallstreetbetsnew with substantially identical wording. That documents repeated coverage, not independent participation or net demand; the sample is too small to support a crowding claim. r/trading212 post, r/Wallstreetbetsnew post.
Catalyst Calendar (next 30 days)
- 2026-09-16: Investor Day disclosure test. Oscar's event page confirms a 9:00 a.m. Eastern Time start. Management's announced agenda covers strategy, financial performance and long-term financial targets; the thesis requires quantified 2027 membership or premiums and subsequent weekly price confirmation above $32.76. Company event page.
What Would Change Our Mind
Failure of the post-August 6 earnings structure would end the price case: a weekly close below $29.83 is the published research boundary. Independently, September 16, 2026 passing without either a quantified 2027 membership range or a quantified 2027 premium framework would end the disclosure thesis, even if that price boundary remained intact.
Success requires the specified disclosure and a subsequent weekly close above the $32.76 August 2026 high before either invalidation occurs. A presentation containing only broader long-term ambitions would not satisfy that test; neither would another daily move above the threshold.
Correlation Notes
FrontierPicks' Managed care & health services assessment classified the group narrative as saturated on August 4, September 6 and September 10, 2026. That is a dated editorial assessment, not a measured correlation or evidence that Oscar's individual narrative has failed.
The September 10 peer group includes CNC, HUM, AVAH and HNGE, but no matched return series is supplied to establish their correlations with Oscar. The single-company case therefore rests on the September 16 disclosure and the published weekly-close conditions, without assuming confirmation from the broader group.
Notes
- Single-segment ACA individual-market insurer: no Medicaid or Medicare Advantage book to offset a weak marketplace quarter, unlike CNC, MOH or ELV.
- Management guides MLR lowest in Q1 and highest in Q4, so quarterly loss ratios are not comparable sequentially; judge each against the 81.5-82.5% FY range.
- Premium is overwhelmingly federally subsidised exchange business, so Congressional premium-tax-credit headlines move the stock independently of operating results.
- Dual-class structure: Class B converts 1:1 into Class A, so insider conversions add Class A float without changing economic ownership.
- Five-year beta 2.38 on a 263.12M float against 308.33M shares outstanding, so index-level and sector moves arrive amplified.
- FY26 guidance assumes no extension of the enhanced ACA premium tax credits, which lapsed 2025-12-31; any enactment is upside outside the model.
Related · shared themes
HUM
Humana Inc.
Humana's Medicare Advantage margin reset supports continuation above the $409.42 adjusted reference high before a daily close below $383. Bernstein maintained its $425 analyst target on 2026-09-09, while October Star Ratings leave the 2028 operating objective unresolved.
CNC
Centene Corporation
Centene's margin-repair case requires sustained earnings guidance and a weekly breakout above $68.72 by its 2026-10-27 results. The 2026-09-09 daily close of $64.06 leaves continuation under pressure; a weekly close below $65 or a reduction of fiscal 2026 adjusted earnings per share guidance above $4.80 invalidates the case.
HNGE
Hinge Health, Inc.
Digital-MSK profitability re-rate broke out in May and was pushed into open price discovery by the 2026-06-09 mid-quarter raise (Q2 to $200–202M, +45%; FY26 to $818–824M). But nine sell-side target hikes in two weeks plus accelerating insider selling mark a late, distribution-prone phase, with no company catalyst until the ~2026-08-04 Q2 print.
CXW
CoreCivic, Inc.
DHS is buying CoreCivic's detention real estate outright — $2.2B gross for four facilities, about $307k/bed — while CoreCivic keeps operating them; proceeds funded $608.5M of debt repayment and a $500M buyback expansion (2026-08-05 release). Shares closed 2026-09-04 at a 52-week high of $34.71 with RSI 56.4, and no company-dated catalyst falls inside the next 30 days.
See also · stocks to watch